Patents by Inventor Nathan Elliott

Nathan Elliott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11947000
    Abstract: Systems, methods, and computer-readable media are described for compact radar systems. In some examples, a compact radar system can include a first set of transmit antennas, a second set of receive antennas, one or more processors, and at least one computer-readable storage medium storing computer-executable instructions which, when executed by the one or more processors, cause the radar system to coordinate digital beam steering of the first set of transmit antennas and the second set of receive antennas, and coordinate digital beam forming with one or more of the second set of receive antennas to detect one or more objects within a distance of the radar system.
    Type: Grant
    Filed: June 6, 2022
    Date of Patent: April 2, 2024
    Assignee: FORTEM TECHNOLOGIES, INC.
    Inventors: Adam Eugene Robertson, Jon Erik Knabenschuh, Lyman Davies Horne, Tyler Drue Park, Matthew Robertson Morin, James David Mackie, Matthew Elliott Argyle, Bryan Alan Davis, Chester Parker Ferry, Daniel Glen Bezzant, Justin Craig Huntington, Nathan James Packard
  • Patent number: 11938295
    Abstract: Ingestible devices can directly deliver therapeutic agents to desired tissue(s) of the GI tract of a subject, such as the submucosa, the mucosa, and/or the mucus layer of the GI tract, and methods of using the same. The ingestible devices can deliver therapeutic agents in a safe, effective, and reliable manner. The disclosure also provides pharmaceutical compositions for use in methods of treating a disease or condition in a subject in need thereof.
    Type: Grant
    Filed: September 15, 2022
    Date of Patent: March 26, 2024
    Assignee: Biora Therapeutics, Inc.
    Inventors: Jeffrey A. Shimizu, Mitchell Lawrence Jones, Mark Sasha Drlik, Iman Niknia, Nathan John Muller, Tuyen Nguyen, Christopher Loren Wahl, Edward Mudge, Nicholas Mark Salt, Nia Eleri Stevens, Stuart Robert Abercrombie, Christopher Ian Bunce, Ryan Elliott Jones, Kevin Howe, Pejman Rahimian, Nelson Quintana
  • Patent number: 11857855
    Abstract: The present invention relates to a method for characterizing a racket head of a ball game racket frame as well as to the representation of a racket head.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: January 2, 2024
    Assignee: Head Technology GmbH
    Inventors: Harald Rosenkranz, Nathan Elliott, Stefan Mohr, Ralf Schwenger
  • Patent number: 11732038
    Abstract: The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an aldehyde group obtained from oxidation of a 2-hydroxyethylamine moiety on the CBA. The invention also provides methods of preparing the conjugates of the present invention. The invention further provides composition and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: August 22, 2023
    Assignee: IMMUNOGEN, INC.
    Inventors: Nathan Elliott Fishkin, Daniel J. Tavares, Lingyun Rui, Luke B. Harris, Manami Shizuka, Michael Louis Miller, Ravi V. J. Chari
  • Patent number: 11521367
    Abstract: The present invention relates to a method for characterizing a string pattern of a ball game racket frame as well as to the representation of a string pattern image of a strung ball game racket frame.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: December 6, 2022
    Assignee: Head Technology GmbH
    Inventors: Nathan Elliott, Ralf Schwenger
  • Patent number: 11505617
    Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Grant
    Filed: January 7, 2021
    Date of Patent: November 22, 2022
    Assignee: IMMUNOGEN, INC.
    Inventors: Wei Li, Nathan Elliott Fishkin, Robert Yongxin Zhao, Michael Louis Miller, Ravi V. J. Chari
  • Publication number: 20220019705
    Abstract: The present invention relates to a method for characterizing the deformation properties of a string pattern of a ball game racket frame as well as to the representation of a string pattern image of a strung ball game racket frame.
    Type: Application
    Filed: July 16, 2021
    Publication date: January 20, 2022
    Applicant: Head Technology GmbH
    Inventors: Stefan MOHR, Daniel LAU, Nathan ELLIOTT
  • Publication number: 20220019831
    Abstract: The present invention relates to a method for characterizing a string pattern of a ball game racket frame as well as to the representation of a string pattern image of a strung ball game racket frame.
    Type: Application
    Filed: July 16, 2021
    Publication date: January 20, 2022
    Applicant: Head Technology GmbH
    Inventors: Nathan ELLIOTT, Ralf SCHWENGER
  • Publication number: 20220016503
    Abstract: The present invention relates to a method for characterizing a racket head of a ball game racket frame as well as to the representation of a racket head.
    Type: Application
    Filed: July 16, 2021
    Publication date: January 20, 2022
    Applicant: Head Technology GmbH
    Inventors: Harald ROSENKRANZ, Nathan Elliott, Stefan Mohr, Ralf Schwenger
  • Publication number: 20210299271
    Abstract: The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an aldehyde group obtained from oxidation of a 2-hydroxyethylamine moiety on the CBA. The invention also provides methods of preparing the conjugates of the present invention. The invention further provides composition and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.
    Type: Application
    Filed: February 12, 2021
    Publication date: September 30, 2021
    Inventors: Nathan Elliott Fishkin, Daniel J. Tavares, Lingyun Rui, Luke B. Harris, Manami Shizuka, Michael Louis Miller, Ravi V.J. Chari
  • Publication number: 20210238301
    Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Application
    Filed: January 7, 2021
    Publication date: August 5, 2021
    Inventors: Wei Li, Nathan Elliott Fishkin, Robert Yongxin Zhao, Michael Louis Miller, Ravi V.J. Chari
  • Patent number: 11006788
    Abstract: A product dispenser for the dispensing of a product which will show active visual content to proximate viewers. A visual display module is attached to a user-facing surface of the dispenser cover of a product dispenser, to display active visual content to viewers. The active visual content displayed on the active media surface of the dispenser cover could take many forms including changing electronic displays or a translucent surface which can be optionally illuminated or emphasized based on a controller and power source. The product dispenser can be supplied with the visual display module in place on the dispenser cover, or an OEM product dispenser with an insert blank in place on the dispenser cover could also be sold into which the visual display module could be later installed. A media-ready dispenser cover which could be used to retrofit an existing product dispenser with the ability to receive a visual display module is also disclosed.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: May 18, 2021
    Inventors: Trevor Thomas, Paul Drouin, Nathan Elliott, Dwayne Melcher
  • Patent number: 10988531
    Abstract: The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an aldehyde group obtained from oxidation of a 2-hydroxyethylamine moiety on the CBA. The invention also provides methods of preparing the conjugates of the present invention. The invention further provides composition and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: April 27, 2021
    Assignee: IMMUNOGEN, INC.
    Inventors: Nathan Elliott Fishkin, Daniel Tavares, Lingyun Rui, Luke B. Harris, Manami Shizuka, Michael Louis Miller, Ravi V. J. Chari
  • Patent number: 10947315
    Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: March 16, 2021
    Assignee: IMMUNOGEN, INC.
    Inventors: Wei Li, Nathan Elliott Fishkin, Robert Yongxin Zhao, Michael Louis Miller, Ravi V. J. Chari
  • Patent number: 10570212
    Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VII). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: February 25, 2020
    Assignee: IMMUNOGEN, INC.
    Inventors: Wei Li, Michael Louis Miller, Nathan Elliott Fishkin, Ravi V. J. Chari
  • Publication number: 20190276552
    Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Application
    Filed: December 21, 2018
    Publication date: September 12, 2019
    Inventors: Wei Li, Nathan Elliott Fishkin, Robert Yongxin Zhao, Michael Louis Miller, Ravi V.J. Chari
  • Publication number: 20190263924
    Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VII). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.
    Type: Application
    Filed: November 30, 2018
    Publication date: August 29, 2019
    Inventors: Wei Li, Michael Louis Miller, Nathan Elliott Fishkin, Ravi V.J. Chari
  • Patent number: 10364294
    Abstract: The present invention is directed to methods of preparing a conjugate of a cell-binding agent and a drug (such as a cytotoxic compound). The methods comprise the use of an imine reactive compound to enable efficient conjugations of cytotoxic compounds with cell binding agents.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: July 30, 2019
    Assignee: IMMUNOGEN, INC.
    Inventors: Nathan Elliott Fishkin, Michael Louis Miller, Wei Li, Rajeeva Singh
  • Patent number: 10208127
    Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: February 19, 2019
    Assignee: IMMUNOGEN, INC.
    Inventors: Wei Li, Nathan Elliott Fishkin, Robert Yongxin Zhao, Michael Louis Miller, Ravi V. J. Chari
  • Patent number: RE49918
    Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VII). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.
    Type: Grant
    Filed: May 10, 2021
    Date of Patent: April 16, 2024
    Assignee: IMMUNOGEN, INC.
    Inventors: Wei Li, Michael Louis Miller, Nathan Elliott Fishkin, Ravi V. J. Chari